OTLK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 04:00):

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications...

Stats
今日成交量	201 543
平均成交量	659 643
市值	183.47M
EPS	$0 ( 2024-02-13 )
下一个收益日期	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.12
ATR14	$0.0160 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Syntone Ventures Llc	Buy	714 286	Common Stock
2024-04-15	Syntone Ventures Llc	Buy	1 071 429	Warrant (Right to Buy)
2024-03-28	Haddadin Yezan Munther	Buy	1 882	Common Stock
2024-03-20	Trenary C Russell Iii	Buy	455 000	Stock Option (Right to Buy)
2024-03-20	Evanson Jeff	Buy	25 000	Stock Option (Right to Buy)

INSIDER POWER
91.91
Last 99 transactions
Buy: 132 469 020 \| Sell: 31 433 684

音量相关性

長: -0.28 (neutral)

短: -0.38 (neutral)

Signal:(52.182) Neutral

Outlook Therapeutics Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Outlook Therapeutics Inc 相关性 - 货币/商品

0.34
( neutral )

-0.18
( neutral )

0.00
( neutral )

0.20
( neutral )

-0.37
( neutral )

-0.35
( neutral )

Outlook Therapeutics Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-44 188.00 (0.00 %)
EPS:	$-4.72

FY	2023
营收:	$0
毛利润:	$-44 188.00 (0.00 %)
EPS:	$-4.72

FY	2022
营收:	$0
毛利润:	$-204 694 (0.00 %)
EPS:	$-6.23

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.350

Financial Reports:

No articles found.

Outlook Therapeutics Inc

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.